Literature DB >> 33655886

Pathologic Features Associated With Molecular Subtypes of Well-Differentiated Thyroid Cancer.

Alice L Tang1, Richard T Kloos2, Benjamin Aunins3, Tammy M Holm4, Mara Y Roth5, Michael W Yeh6, Gregory W Randolph7, Meredith E Tabangin8, Mekibib Altaye8, David L Steward3.   

Abstract

OBJECTIVE: To determine the association between pathologic features and molecular classes (BRAF-like, RAS-like, and non-BRAF-like non-RAS-like [NBNR]).
METHODS: Retrospective review of a merged database containing 676 patients, 84% (571/676) were assigned to a molecular class from publicly accessible sequenced data of thyroid neoplasms.
RESULTS: The merged cohort included 571 neoplasms: 353 (62%) BRAF-like, 172 (30%) RAS-like, and 46 (8.1%) NBNR. Lymph node metastasis (any N1 disease) was present in 166/337 (49%) of BRAF-like, 23/164 (14%) of RAS-like, and 0/46 (0%) of NBNR and are significantly different (P < .001). Gross extra-thyroidal extension was observed in 27 patients, including 24/331 (7%) of BRAF-like, 2/160 (1%) of RAS-like, and 1/46 (2%) of NBNR (P = .01). N1B lymph node metastases or T4 disease was present in 74/333 (22%) of BRAF-like, 10/160 (6%) of RAS-like, and 1/46 (2%) of NBNR (P < .0001). Distant metastasis was present in 4/151 (2.6%) of BRAF-like, 2/50 (4%) of RAS-like and 0/46 for NBNR (P = .627). Angioinvasion was present in 0/81 (0%) of BRAF-like, 3/53 (6%) of RAS-like, and 3/46 (7%) of NBNR (P = .08); and multifocality was present in 27/81 (33%) of BRAF-like, 9/53 (17%) of RAS-like, and 1/46 (2%) for NBNR (P = .0001).
CONCLUSION: Pathological features of metastasis, gross extra-thyroidal extension, and multifocality were more prevalent in BRAF-like samples compared to RAS-like and NBNR. A trend towards increased frequency of angioinvasion in RAS-like and NBNR cancers compared to BRAF-like samples was observed. Further studies are needed to evaluate if preoperative knowledge of molecular mutations in thyroid tumors aids in decision-making regarding extent of surgery.
Copyright © 2020 AACE. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BRAF mutation; RAS mutation; molecular diagnostics; thyroid cancer

Year:  2020        PMID: 33655886     DOI: 10.1016/j.eprac.2020.09.003

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  2 in total

1.  BRAFV600E mutation test on fine-needle aspiration specimens of thyroid nodules: Clinical correlations for 4600 patients.

Authors:  Huang Chen; Aiping Song; Ye Wang; Yifan He; Jie Tong; Jinxi Di; Chun Li; Zhongren Zhou; Xiaopin Cai; Dingrong Zhong; Jiping Da
Journal:  Cancer Med       Date:  2021-12-01       Impact factor: 4.452

2.  Novel Genomic Roadmaps and Their Clinical Translation Ahead.

Authors:  Erik K Alexander
Journal:  J Clin Endocrinol Metab       Date:  2022-01-18       Impact factor: 5.958

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.